Interview: Patrice Carayon – CEO, Chiesi France
Patrice Carayon, CEO of Chiesi France, reveals how Chiesi is one of a select few international mid-size pharmaceutical companies in France to have both an R&D and production footprint to…
Chiesi is an international company based in Parma, with 80 years of experience and a strong focus on research, development, production and the commercialisation of innovative medicines in the Respiratory, Neonatology, Rare Disease and Special Care Therapeutic Areas.With a turnover of more than €1.3 billion sales, Chiesi is among the top 50 pharmaceutical companies in the world. They have production sites are in Parma, Italy, Blois (France) and Santana De Parnaiba (Brazil) and R&D centres in Parma (Italy), Paris (France), Rockville (USA), Chippenham (UK).
Chiesi is one of a select few international mid-size pharmaceutical companies in France to have both an R&D and production footprint to accompany its commercial activities. In 2013 Chiesi announced an investment of 22 million euros (USD 23.90 million) in their production site in Blois. Significant investments in manufacturing capacity have been made. Previously, the site employed 60 people, by the end of 2016 this number will have almost doubled.
Chiesi was established in France in 1992 through its subsidiary ProMedica. In 1999, the Italian group strengthened its presence with the acquisition of Logeais Group. Today, the French subsidiary is directed by Patrice Carayon. It represents 8 percent of total Group sales with a turnover of 104 million euros in 2014. Subsidiary of primary importance, France is Chiesi´s fifth most important market.
Contact
Address: Immeuble le Doublon – 11 Avenue Dubonnet, 92400 Courbevoie – France
Tel: 33 1 47688899
Patrice Carayon, CEO of Chiesi France, reveals how Chiesi is one of a select few international mid-size pharmaceutical companies in France to have both an R&D and production footprint to…
The basis of the pharmaceutical business model is changing. Take sales forces for instance, what will be the composition and daily routine? How much mixed media will it require? Currently,…
The Contract Development and Manufacturing Organization (CDMO) sector has flousished in recent years as Big Pharma has shifted its attention to its core R&D activities and outsourced other supply chain…
Despite an uncertain macro-economic environment, the French health technology sector continues its growth trajectory, demonstrating both entrepreneurial dynamism and maturity, according to the new edition of the France Biotech study…
The latest news from French pharma, including fears of medicine shortages and suspension of online sales of paracetamol, CARMAT’s artificial heart product entering a study in France, Sanofi’s expanded deal…
An early bronchiolitis outbreak has put French paediatric hospital services under pressure and forced the government to react with the provision of EUR 150 million in emergency funds, but this…
French mid-cap Servier has launched a new visual identity and logo and announced an ambitious 2030 growth plan with an increased focus on hard-to-treat cancers. Servier, which is governed…
Exor, led by Fiat brand heirs the Agnelli family, has signed a partnership agreement for an investment of EUR 833 million in the also family-owned French holding, Institut Mérieux, known…
The head of the French Chamber of Commerce in Egypt, Karim Wissa, dives into the current state of the Egyptian economy, the reasons behind its healthcare boom, explains why companies…
France is Europe’s 4th largest pharmaceutical manufacturer, having produced pharmaceuticals valued at €21.9 billion in 2019. In recent years, the French contract development and manufacturing organisation (CDMO) market has seen…
When British executive Paul Hudson joined French pharma Sanofi back in 2019, he was quick to launch a “play to win” strategy, shedding underperforming areas and doubling down on its…
French mid-cap pharma Ipsen achieved total sales of EUR 2.869 billion in 2021, a 12.3 percent increase on results from the pandemic-affected 2020 total. The company also announced plans to…
The latest news from French pharma, including AI-based biotech Owkin’s new status as a USD one billion-valued unicorn following fresh investment from Sanofi. Also included is another deal for Sanofi,…
The Top Five countries in Europe for pharma production. All located in Western Europe, Switzerland punches well above its weight to take top spot. This data is taken from the 2021…
See our Cookie Privacy Policy Here
